Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Assets (2016 - 2025)

Historic Assets for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to $89.6 million.

  • Lineage Cell Therapeutics' Assets fell 720.02% to $89.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $89.6 million, marking a year-over-year decrease of 720.02%. This contributed to the annual value of $113.2 million for FY2024, which is 1207.59% up from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Assets of $89.6 million as of Q3 2025, which was down 720.02% from $90.8 million recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Assets ranged from a high of $174.5 million in Q4 2021 and a low of $89.6 million during Q3 2025
  • Moreover, its 5-year median value for Assets was $113.2 million (2023), whereas its average is $118.4 million.
  • In the last 5 years, Lineage Cell Therapeutics' Assets soared by 6169.21% in 2021 and then crashed by 2915.06% in 2022.
  • Quarter analysis of 5 years shows Lineage Cell Therapeutics' Assets stood at $174.5 million in 2021, then fell by 29.15% to $123.7 million in 2022, then fell by 18.31% to $101.0 million in 2023, then increased by 12.08% to $113.2 million in 2024, then fell by 20.83% to $89.6 million in 2025.
  • Its Assets stands at $89.6 million for Q3 2025, versus $90.8 million for Q2 2025 and $111.8 million for Q1 2025.